Aprea Therapeutics (APRE) Treatment of Acute Myeloid Leukemia Receives FDA Orphan Status

April 8, 2021 9:23 AM EDT
Get Alerts APRE Hot Sheet
Price: $4.30 -0.46%

Overall Analyst Rating:
    NEUTRAL (Down Down)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Aprea Therapeutics (NASDAQ: APRE) treatment of acute myeloid leukemia, eprenetapopt, received FDA orphan status.

Generic Name: eprenetapopt
Date Designated: 04/07/2021
Orphan Designation: Treatment of Acute Myeloid Leukemia
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Aprea Therapeutics, Inc.
535 Boylston Street
2nd Floor
Boston, Massachusetts 02116
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

FDA